#582: GLP-1 Agonists: Side Effects, Management and Diet – Dr. Spencer Nadolsky

In Podcasts by Danny LennonLeave a Comment

Listen Here:

For a full list of apps, go here. Or simply search “Sigma Nutrition” in your app of choice.
Or listen directly on the Sigma website here.

Introduction

GLP-1 receptor agonists have emerged as a groundbreaking tool in obesity treatment. In this episode, Dr. Spencer Nadolsky (an obesity specialist) explains how these medications are now yielding unprecedented weight loss outcomes in people with obesity. 

The discussion centers on GLP-1 agonist drugs like semaglutide and tirzepatide: how they work, how much weight loss they can produce, and why they represent a paradigm shift in obesity management. 

Importantly, the conversation addresses practical aspects of using these drugs, including managing their side effects and optimizing patients’ diet and lifestyle while on therapy.

This topic is of great significance to nutrition science, clinical practice, and public health. Obesity is a chronic, relapsing condition that has proven difficult to treat with lifestyle changes alone. The advent of GLP-1 agonists offers new hope by inducing weight loss levels previously seen only with surgical interventions. 

Understanding these medications is crucial for healthcare professionals: it enables evidence-based prescribing, proper patient counseling on diet and side effects, and integration of medication with lifestyle interventions. 

Discussing safety and long-term use is vital, as millions more patients might use these drugs in coming years. From a public health perspective, GLP-1 agonists prompt debates about access and cost, given their high price and life-changing potential.

Guest Information

Dr. Spencer Nadolsky

Dr. Spencer Nadolsky is a board-certified obesity and lipid specialist physician whose clinical work focuses on evidence-based management of metabolic diseases through lifestyle and medical interventions. With a background in family medicine and exercise physiology, he emphasizes practical, data-driven strategies for improving cardiometabolic health and addressing conditions such as obesity, dyslipidemia, and insulin resistance. He also serves as the founder and director of Vineyard, a physician-led virtual care platform dedicated to helping patients achieve sustainable weight and metabolic outcomes through continuous, personalized support grounded in sound clinical evidence.

Timestamps

  • [03:25] Conversation with Dr. Spencer Nadolsky begins
  • [05:24] Mechanism and types of GLP-1 medications
  • [07:55] Efficacy and weight loss results
  • [16:53] Common side effects and management
  • [22:57] Muscle loss concerns and clinical insights
  • [28:09] Addressing nutritional concerns with GLP-1 medications
  • [29:38] Exploring potential benefits beyond weight loss
  • [33:48] Marketing and misconceptions around GLP-1
  • [36:59] Public health and accessibility issues
  • [43:25] Future research
  • [46:16] Key ideas segment (Premium-only)

Premium Content

You’re currently logged-in as a Premium subscriber. Access you content below.

You are currently not signed-in as a Premium subscriber.

To view our Premium content, please to your account or subscribe to Premium.

Not a Premium subscriber? Subscribe here!

Return to top of page

Leave a Comment